• Alvotech is trading 14.4% up at ISK 445.00, extending a sharp rebound.
  • The rally follows news on July 29 that the U.S. FDA closed its May 2026 inspection of Alvotech's Reykjavik manufacturing facility with a Voluntary Action Indicated (VAI) classification.
  • This positive regulatory outcome signals only non-critical improvements are needed, strengthening the company's biosimilar development and production.